crypto have- Top Featured snippets

Zijiang Enterprise set up a packaging company in Hubei with 20 million yuan. According to the enterprise search APP, Hubei Zijiang Packaging Co., Ltd. was recently established, with Shao Chunjiang as the legal representative and a registered capital of 20 million yuan. Its business scope includes: the production of plastic packaging containers and tools for food; Sales of plastic packaging containers, tools and products for food. Enterprise investigation shows that the company is wholly owned by Zijiang Enterprise.It is reported that Baidu and Geely are taking the transfer process to pay the social security arrears for employees of Extreme Vietnam in November. According to media reports, on the evening of December 12, the CEO of Extreme Vietnam Xia Yiping and Geely and Baidu held a closed meeting. After several rounds of communication, Baidu and Geely are taking the transfer process to pay the arrears of social security for employees in November. Shareholders Geely and Baidu set up an emergency team to participate remotely. In response to this news, Baidu and Geely did not comment. (Sina Technology)The central bank's open market today launched a 7-day reverse repurchase operation of 205.1 billion yuan, and the operating interest rate was flat at 1.50%. Today, 190.9 billion yuan of 7-day reverse repurchase expired, and the net investment on that day was 14.2 billion yuan.

Chongda Technology: Five measures are taken to deal with the challenges and opportunities of industry development. Chongda Technology (002815) said in the online collective reception day of investors on December 12 that the company's measures to deal with the challenges and opportunities of industry development include: optimizing product structure, continuing to promote the optimization and upgrading of product structure, increasing R&D investment and market expansion in the field of high-end PCB boards, and accelerating the introduction of high-value customers and orders; Improve production efficiency and cost control; Accelerate the pace of capacity expansion, and promote the speed of capacity improvement of Dalian Plant, Zhuhai No.1 Plant and Zhuhai No.2 Plant in an orderly manner; According to market demand, adjust product price strategy in real time to improve profitability; Accelerate the construction of production base in Thailand, actively participate in international competition and cooperation, and enhance the company's visibility and influence in the global PCB market.The scale of A500-related funds exceeded 240 billion yuan, and the scale of CSI A500ETF leader (563,800) jumped to the first place in Shanghai. On December 12, the total scale of funds tracking CSI A500 index reached 242.1 billion yuan, which was the fastest index in the history of A-share. In addition, the CSI A500 Index also contributed about one third of the increase in scale index funds since September. Among them, CSI A500ETF leader (563800) has attracted the most gold since its listing on November 18th, with a net inflow of 14.2 billion yuan, and its latest scale has exceeded 16.5 billion yuan, ranking first in Shanghai.The Shenzhen Stock Exchange terminated the audit of four bond projects with a total amount of 5.879 billion yuan. On December 13, the Shenzhen Stock Exchange recently terminated the audit of four bond projects with a total amount of 5.879 billion yuan, and the varieties were small public offerings and private placements.

The three major stock indexes opened lower and went lower. The Shenzhen Stock Exchange Index and the Growth Enterprise Market Index all fell more than 1%, and the Shanghai Composite Index fell 0.88%.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.Japan's Topix index fell to 1%.